Ken Griffin Aytu Biopharma, Inc Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$1.35 - $2.95 $14,253 - $31,146	10,558 Added 12.06%	98,127 $132,000
Q3 2021 Nov 15, 2021	BUY	$2.78 - $5.12 $175,668 - $323,532	63,190 Added 259.2%	87,569 $252,000
Q2 2021 Aug 16, 2021	SELL	$4.73 - $7.56 $1,806 - $2,887	-382 Reduced 1.54%	24,379 $122,000
Q1 2021 May 17, 2021	SELL	$6.23 - $9.88 $367,040 - $582,080	-58,915 Reduced 70.41%	24,761 $188,000
Q4 2020 Feb 16, 2021	BUY	$5.98 - $13.5 $500,382 - $1.13 Million	83,676 New	83,676 $500,000

Ticker AYTU
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 62,432,700
Market Cap $88.7M
Description
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT f...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.